Sequoia Financial Advisors LLC Sells 21,947 Shares of Pfizer Inc. $PFE

Sequoia Financial Advisors LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 6.2% during the second quarter, HoldingsChannel.com reports. The fund owned 332,178 shares of the biopharmaceutical company’s stock after selling 21,947 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $7,999,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at $26,000. HFM Investment Advisors LLC grew its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares in the last quarter. Finally, Abound Financial LLC bought a new position in shares of Pfizer during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Citigroup lifted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

Pfizer stock opened at $26.77 on Friday. The stock has a 50-day simple moving average of $25.12 and a 200 day simple moving average of $26.20. The stock has a market capitalization of $152.60 billion, a price-to-earnings ratio of 35.23 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.